Nakandakare E, Garcia R C, Rocha J C, Sperotto G, Oliveira H C, Quintão E C
Lab. Lipids-(LIM/10) Hospital of the University of São Paulo Medical School, Brazil.
Atherosclerosis. 1990 Dec;85(2-3):211-7. doi: 10.1016/0021-9150(90)90113-w.
Simvastatin, 10-40 mg/d (n = 11), bezafibrate, 600 mg/d (n = 6), and gemfibrozil, 1200 mg/d (n = 5) were administered for 12 weeks after a 4-week placebo period to subjects with initial plasma levels (mg/100 ml. mean +/- SD) of cholesterol (346 +/- 77), and of triglycerides (180 +/- 54). Total LDL-C plasma concentration was lowered 32% by simvastatin and 35% by bezafibrate, but only bezafibrate diminished the triglyceride (41%) and increased HDL-C plasma levels (35%). Plasma lipoprotein fractions obtained by discontinuous gradient ultracentrifugation, namely, VLDL, lighter LDL (LDL-1), heavier LDL (LDL-2) and bulk HDL were chemically analyzed. Simvastatin and bezafibrate significantly diminished the quantity of VLDL and LDL-1 particles, although barely modifying their composition. Neither drug influenced the LDL-2 plasma concentration. Bezafibrate increased the total plasma HDL level little interfering with its chemical composition. Gemfibrozil was the least effective of all drugs but decreased the lipid and protein contents and their ratios in VLDL and LDL-2.
对初始血浆水平(毫克/100毫升,均值±标准差)胆固醇为(346±77)、甘油三酯为(180±54)的受试者,在4周安慰剂期后给予辛伐他汀,10 - 40毫克/天(n = 11),苯扎贝特,600毫克/天(n = 6),吉非贝齐,1200毫克/天(n = 5),给药12周。辛伐他汀使总低密度脂蛋白胆固醇(LDL - C)血浆浓度降低32%,苯扎贝特降低35%,但只有苯扎贝特降低了甘油三酯(41%)并提高了高密度脂蛋白胆固醇(HDL - C)血浆水平(35%)。通过不连续梯度超速离心获得的血浆脂蛋白组分,即极低密度脂蛋白(VLDL)、较轻的低密度脂蛋白(LDL - 1)、较重的低密度脂蛋白(LDL - 2)和总高密度脂蛋白进行了化学分析。辛伐他汀和苯扎贝特显著减少了VLDL和LDL - 1颗粒的数量,尽管对其组成几乎没有改变。两种药物均未影响LDL - 2血浆浓度。苯扎贝特增加了总血浆HDL水平,对其化学成分干扰较小。吉非贝齐是所有药物中效果最差的,但降低了VLDL和LDL - 2中的脂质和蛋白质含量及其比例。